Efficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk – A Systematic Review and Meta-Analysis

Open Access

Peer-reviewed

Research Article

Julia Schiffner-Rohe ,

* E-mail: Julia.Schiffner-Rohe@pfizer.com

Affiliation Pfizer Deutschland GmbH, Linkstr. 10, 10785, Berlin, Germany
⨯
Annika Witt,

Affiliation AMS-Advanced Medical Services GmbH, Rosa-Bavarese-Str.5, 80639, Munich, Germany
⨯
Jana Hemmerling,

Affiliation AMS-Advanced Medical Services GmbH, Rosa-Bavarese-Str.5, 80639, Munich, Germany
⨯
Christof von Eiff,

Affiliation Pfizer Pharma GmbH, Linkstr. 10, 10785, Berlin, Germany
⨯
Friedrich-Wilhelm Leverkus

Affiliation Pfizer Deutschland GmbH, Linkstr. 10, 10785, Berlin, Germany
⨯

Reader Comments (0)

Medical risk factors
Is the Subject Area "Medical risk factors" applicable to this article?

Thanks for your feedback.
Metaanalysis
Is the Subject Area "Metaanalysis" applicable to this article?

Thanks for your feedback.
Pneumonia
Is the Subject Area "Pneumonia" applicable to this article?

Thanks for your feedback.
Nursing homes
Is the Subject Area "Nursing homes" applicable to this article?

Thanks for your feedback.
Vaccine development
Is the Subject Area "Vaccine development" applicable to this article?

Thanks for your feedback.
Randomized controlled trials
Is the Subject Area "Randomized controlled trials" applicable to this article?

Thanks for your feedback.
HIV vaccines
Is the Subject Area "HIV vaccines" applicable to this article?

Thanks for your feedback.
Conjugate vaccines
Is the Subject Area "Conjugate vaccines" applicable to this article?

Thanks for your feedback.